As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up awareness of the drug among its expanded patient pool. To that end ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more ...

Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2 ...

In interviews with Fierce Pharma Marketing at Fierce’s annual Digital Pharma East event in Philadelphia last week, marketing leaders from Bayer, Daiichi Sankyo and argenx discussed that slower ...

Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...

On Tuesday, Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) shares maintained a positive outlook as TD Cowen sustained its Buy rating and JPY46.00 price target on the company's stock.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...